Key result
Systematic review protocol evaluates Buyang-Huanwu Decoction efficacy and safety in acute ischemic stroke.
Systematic Review
Answers are grounded in this paper and cite their sources.
BACKGROUND: We designed this study to assess the effects and safety of Buyang-Huanwu Decoction (BYHWD) for the treatment of patients with acute ischemic stroke (AIS). METHODS: Electronic databases of Cochrane Library, EMBASE, MEDLINE, CINAHL, PsycINFO, Scopus, Allied and Complementary Medicine Database, VIP Database, and China National Knowledge Infrastructure will be comprehensively and systematically searched from initial time of each electronic database to the present without limitations of language and publication status. Randomized controlled trials on BYHWD alone against any other interventions for the treatment of AIS will be included. All process of study selection, data collection, and methodological quality assessment will be independently undertaken by 2 investigators. Cochrane risk of bias tool and RevMan 5.3 software will be utilized for the performance of methodological quality assessment and statistical analysis, respectively. RESULTS: This study will summarize most recent high quality evidence on investigating the effects and safety of BYHWD alone against any other interventions for the treatment of patients with AIS. CONCLUSIONS: The findings of this study will provide helpful evidence for the clinical practice for patients with AIS using BYHWD, as well as the relevant future researches.Study registration number: INPLASY202040169.
No takes yet. Share an insight, caveat, or question.
Jiang et al. (2020) conducted a systematic review in acute ischemic stroke. Buyang-Huanwu Decoction (BYHWD) vs. any other interventions was evaluated. This protocol outlines a planned systematic review to evaluate the effects and safety of Buyang-Huanwu Decoction against other interventions for the treatment of acute ischemic stroke.
Synapse has enriched 10 related papers. Consider them for comparative context: